Second Department of Gynecology, Medical University of Lublin , Lublin, Poland.
Expert Opin Pharmacother. 2021 Jan;22(1):9-17. doi: 10.1080/14656566.2020.1809652. Epub 2020 Sep 29.
Vibegron is a very selective new β3-adrenergic receptor agonist introduced recently to clinical practice for OAB patients, which offers an alternative option for to antimuscarinic drugs.
This review presents the current knowledge concerning the mechanism of action, pharmacokinetics, and pharmacodynamics of vibegron. Moreover, it presents an overview of preclinical and phase II and phase III clinical studies on the efficacy, tolerability, and safety of this agent in patients suffering from OAB.
Clinical studies confirmed efficacy and safety of vibegron in OAB patients. Vibegron differ from well-known mirabegron with regards to its pharmacological profile because it is metabolized independently from CYP3A4, 2D6, or 2C9 and therefore is less likely to cause a drug-drug interaction. Moreover, since this drug does not penetrate the blood-brain barrier, it could become the drug of choice in OAB patients with cognitive impairment. These properties have paved the way in near future for better-tailored treatments for OAB patients.
维贝格龙是一种新型的β3-肾上腺素能受体激动剂，最近被引入临床实践，用于治疗 OAB 患者，为抗毒蕈碱药物提供了另一种选择。
本文介绍了维贝格龙的作用机制、药代动力学和药效学的最新知识。此外，本文还概述了维贝格龙在 OAB 患者中的疗效、耐受性和安全性的临床前和 II 期和 III 期临床研究。
临床研究证实了维贝格龙在 OAB 患者中的疗效和安全性。维贝格龙与广为人知的米拉贝隆在药理学特性上有所不同，因为它的代谢与 CYP3A4、2D6 或 2C9 无关，因此不太可能引起药物相互作用。此外，由于该药物不会穿透血脑屏障，因此它可能成为认知障碍的 OAB 患者的首选药物。这些特性为 OAB 患者的量身定制治疗铺平了道路。
